Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00032269.xml

CC BY-ND-NC 4.0 · SynOpen 2018; 02(01): 0036-0040
DOI: 10.1055/s-0036-1591918
DOI: 10.1055/s-0036-1591918
letter
Iodine as a New Catalyst for the Condensation of 2-Hydroxy-2,2′-bisindan-1,1′,3,3′-tetrone with Cyclic Enaminones: Synthesis of Spiro-dihydropyridine Derivatives under Acid-Free Conditions
Further Information
Publication History
Received: 05 November 2017
Accepted after revision: 16 January 2018
Publication Date:
01 February 2018 (online)

Abstract
Iodine has been used as a new catalyst for the synthesis of spiro-dihydropyridine derivatives by the condensation of cyclic enaminones and 2-hydroxy-2,2′-bisindan-1,1′,3,3′-tetrone.
Supporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0036-1591918.
- Supporting Information
-
References
- 1 Moghaddam FM. Khodabakhshi MR. Aminaee M. Tetrahedron Lett. 2014; 55: 4720
- 2 Alizadeh A. Saberi V. Mokhtari J. Synlett 2013; 24: 1825
- 3 Zhang J. Gao Q. Wu X. Geng X. Wu YD. Wu A. Org. Lett. 2016; 18: 1686
- 4 Hao WJ. Wang SY. Ji SJ. ACS Catal. 2013; 3: 2501
- 5 Deiters A. Martin SF. Chem. Rev. 2004; 104: 2199
- 6 Thansandote P. Lautens M. Chem. Eur. J. 2009; 15: 5874
- 7 Zhu L. Cheng L. Zhang Y. Xie R. You J. J. Org. Chem. 2007; 72: 2737
- 8 Martín R. Rodriguez RiveroM. Buchwald SL. Angew. Chem. Int. Ed. 2006; 45: 7079
- 9a Safak C. Simsek R. Mini-Rev. Med. Chem. 2006; 6: 747
- 9b Katoh M. Nakajima M. Shimada N. Yamazaki H. Yokoi T. Eur. J. Clin. Pharmacol. 2000; 55: 843
- 9c Ruggenenti P. Perna A. Benini R. Remuzzi G. J. Am. Soc. Nephrol. 1998; 9: 2096
- 10a Glossmann H. Ferry DR. Goll A. Striessnig J. Zernig G. Arzneim.-Forsch. 1985; 35: 1917
- 10b Matowe WC. Akula M. Knaus EE. Wolowyk MW. Proc. West. Pharmacol. Soc. 1989; 32: 305
- 11 Vo D. Matowe WC. Ramesh M. Iqbal N. Wolowyk MW. Howlett SE. Knaus EE. J. Med. Chem. 1995; 38: 2851
- 12a Vo D. Nguyen JT. McEwen C.-A. Shan R. Knaus EE. Drug Dev. Res. 2002; 56: 1
- 12b Edraki N. Mehdipour AR. Khoshneviszadeh M. Miri R. Drug Discovery Today 2009; 14: 1058
- 13 Zhang YL. Li YF. Wang JW. Yu B. Shi YK. Liu HM. Steroids 2016; 109: 22
- 14 Parameswarappa SG. Pigge FC. J. Org. Chem. 2012; 77: 8038
- 15 Tejedor D. Cotos L. Méndez-Abt G. García-Tellado F. J. Org. Chem. 2014; 79: 10655
- 16 Auria-Luna F. Marqués-López E. Mohammadi S. Heiran R. Herrera RP. Molecules 2015; 20: 15807
- 17a Senczyszyn J. Brice H. Clayden J. Org. Lett. 2013; 15: 1922
- 17b Debnath K. Singha K. Pramanik A. RSC Adv. 2015; 5: 31866
- 17c Sarkar P. Mukhopadhyay C. Tetrahedron Lett. 2016; 57: 4306
- 18a Campagna F. Carotti A. Casini G. Ferappi M. Gazz. Chim. Ital. 1983; 113: 507
- 18b Schoenberg A. Singer E. Chem. Ber. 1970; 103: 3871
- 19 Das S. Pramanik A. Fröhlich R. Patra A. Tetrahedron 2004; 60: 10197
- 20 Das S. Fröhlich R. Pramanik R. J. Chem. Res. 2005; 9: 572
- 21 Das S. Fröhlich R. Pramanik R. J. Chem. Res. 2007; 1: 5
- 22 Ashis K. Mukherjee S. Pramanik R. RSC Adv. 2015; 130: 107847
- 23 Ashis KR. Pramanik R. Mol. Diversity 2015; 3: 459
- 24a Moghaddam FM. Bardajee RG. Ismaili H. Dokht M. Taimoory S. Synth. Commun. 2006; 36: 2543
- 24b Moghaddam FM. Khodabakhshi MR. Aminaee M. Tetrahedron Lett. 2014; 55: 4720
- 25 Typical procedure for the synthesis of spiro-dihydropyridines 3a–j: A mixture of 2-hydroxy-2,2′-bisindan-1,1′,3,3′-tetrone 1 (1 mmol), cyclic enaminone 2a–f (1 mmol) and molecular iodine (20 mol%) in DMSO (4 mL) was stirred at 100 °C for 4 h. After completion of the reaction (monitored by TLC, ethyl acetate/n-hexane, 1:2) the reaction mixture was allowed to cool to room temperature. Water was added and the precipitate was filtered off and washed with acetone to give the product 3a–j.
- 26 Synthesis of 2-hydroxy-2,2′-bisindan-1,1′,3,3′-tetrone 1: A mixture of 1,3-indandione (10 mmol), ninhydrin (10 mmol), and triethylamine (1 mmol) in EtOH (50 mL) was stirred at room temperature for 5 h. The precipitate was filtered and washed with EtOH (2 × 5 mL) to give 1. Yellow powder; mp 187–190 °C; 1H NMR (500 MHz, CDCl3): δ = 8.00–7.93 (m, 2 H, Ar), 7.92–7.83 (m, 6 H, Ar), 5.47 (s, 1 H, OH), 3.96 (s, 1 H, CH); 13C NMR (125 MHz, CDCl3): δ = 197, 196, 142, 141, 137, 136, 124, 124, 76, 53. Analytical data for spiro[indene-2,5′-indeno[2′,1′:5,6]pyrido[2,3-d]pyrimidine]-1,2′,3,4′,6′(1′H,3′H,11′H)-pentaone (3a): Yield: 0.361 g (91%); red powder; mp 212–215 °C (dec.); IR (KBr): 3249, 2917, 1710, 1690, 1666 cm–1; 1H NMR (500 MHz, D2O): δ = 7.89–7.85 (m, 4 H, Ar-H), 7.36 (d, J = 6.9 Hz, 1 H, Ar-H), 7.24–7.17 (m, 2 H, Ar-H), 7.00 (d, J = 6.9 Hz, 1 H, Ar-H); 13C NMR (125 MHz, D2O): δ = 209, 187, 173, 170, 165, 162, 141, 138, 137, 136, 131, 130, 122, 119, 119, 100, 92, 56; Anal. Calcd for C22H11N3O5: C, 66.50; H, 2.79; N, 10.58. Found: C, 65.90; H, 2.81; N, 10.61; HRMS: m/z [M+H]+ calcd. for C22H11N3O5: 398.0777; found: 398.0775.